| one can suppose that the structural features of DNA are involved in the formation of ERBB2-containing amplicon borders in breast cancer cells and the data are of importance for understanding the mechanisms of oncogene amplification. | breast, |
| MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Delta16 mediated breast tumorigenesis and reverse trastuzumab resistance. | breast, |
| Gastric cancer cells that express the HER-2 oncogene spur the activation of NF-kappaB that can upregulate the expression of ICAM-1 and induce the expression of MMP-9, which hydrolyzes ICAM-1 into s-ICAM-1 to promote tumor immune escape. | gastric, |
| Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. | breast, |
| Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. | breast, |
| HER-2/neu oncogene protein and prognosis in breast cancer. | breast, |
| Expression of the c-erbB-2 proto-oncogene protein in human breast cancer. | breast, |
| [Cell cycle specific expression of the HER-2/NEU oncogene in breast cancer cell lines]. | breast, |
| [Oncogene organization and expression in breast cancer exemplified by proto-oncogene c-erb B2]. | breast, |
| The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. | breast, |
| c-erbB-2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study. | gastric, |
| Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. With special reference to their prognostic significance in carcinoma. | breast, |
| Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. | breast, |
| Oncogenic HER2 fusions in gastric cancer. | gastric, |
| The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. | pancreatic, |
| Data show that proto-oncogene protein HER-2 overexpression occurs in only 8% of patients with colorectal cancer (CRLM) but with 75% of cases proto-oncogene protein HER-3 is frequently overexpressed in CRLM. | colorectal, |
| [Non-small cell lung cancer: HER2 oncogene status]. | lung, |
| Data suggest that AMP-activated protein kinase (AMPK) regulates HER-2 proto-oncogene protein and epidermal growth factor receptor (EGFR) in HER2-amplified breast cancer cells and activation of AMPK might provide therapeutic benefit in such cancers. | breast, |
| PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. | uterine, |
| Data showthat erbB-2 receptor protein-tyrosine kinase (HER2) represents an oncogene in ovarian cancer, and suggest that targeting this tyrosine kinase with T-DM1 may be therapeutically effective, especially in ovarian tumors with high content of HER2. | ovarian, |